PT2929880T - Agente terapêutico para doenças que têm por base o efeito inibidor do fator inibidor da migração de macrófagos - Google Patents

Agente terapêutico para doenças que têm por base o efeito inibidor do fator inibidor da migração de macrófagos

Info

Publication number
PT2929880T
PT2929880T PT148268113T PT14826811T PT2929880T PT 2929880 T PT2929880 T PT 2929880T PT 148268113 T PT148268113 T PT 148268113T PT 14826811 T PT14826811 T PT 14826811T PT 2929880 T PT2929880 T PT 2929880T
Authority
PT
Portugal
Prior art keywords
therapeutic agent
disease based
macrophage migration
inhibitory effect
inhibitory
Prior art date
Application number
PT148268113T
Other languages
English (en)
Inventor
Tanaka Keiichi
Morimoto Kimiko
Original Assignee
Toyama Chemical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Toyama Chemical Co Ltd filed Critical Toyama Chemical Co Ltd
Publication of PT2929880T publication Critical patent/PT2929880T/pt

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/02Drugs for disorders of the nervous system for peripheral neuropathies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D311/00Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C07D311/22Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D311/00Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C07D311/22Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4
    • C07D311/24Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4 with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D311/00Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C07D311/22Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4
    • C07D311/26Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4 with aromatic rings attached in position 2 or 3
    • C07D311/28Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4 with aromatic rings attached in position 2 or 3 with aromatic rings attached in position 2 only
    • C07D311/30Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4 with aromatic rings attached in position 2 or 3 with aromatic rings attached in position 2 only not hydrogenated in the hetero ring, e.g. flavones

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pyrane Compounds (AREA)
PT148268113T 2013-07-18 2014-07-17 Agente terapêutico para doenças que têm por base o efeito inibidor do fator inibidor da migração de macrófagos PT2929880T (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2013149690 2013-07-18

Publications (1)

Publication Number Publication Date
PT2929880T true PT2929880T (pt) 2016-11-08

Family

ID=52346269

Family Applications (2)

Application Number Title Priority Date Filing Date
PT161694146T PT3078372T (pt) 2013-07-18 2014-07-17 Agente terapêutico para doenças que têm por base o efeito inibidor do fator inibidor da migração de macrófagos
PT148268113T PT2929880T (pt) 2013-07-18 2014-07-17 Agente terapêutico para doenças que têm por base o efeito inibidor do fator inibidor da migração de macrófagos

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PT161694146T PT3078372T (pt) 2013-07-18 2014-07-17 Agente terapêutico para doenças que têm por base o efeito inibidor do fator inibidor da migração de macrófagos

Country Status (23)

Country Link
US (3) US20150353519A1 (pt)
EP (2) EP2929880B1 (pt)
JP (2) JP5802868B2 (pt)
CN (1) CN105407887B (pt)
AU (1) AU2014291149B2 (pt)
CA (1) CA2918325C (pt)
CY (2) CY1118140T1 (pt)
DK (2) DK3078372T3 (pt)
ES (2) ES2593527T3 (pt)
HK (1) HK1222556A1 (pt)
HR (2) HRP20161317T1 (pt)
HU (2) HUE034661T2 (pt)
IL (1) IL243550B (pt)
LT (2) LT2929880T (pt)
NO (1) NO3078372T3 (pt)
PL (2) PL3078372T3 (pt)
PT (2) PT3078372T (pt)
RS (2) RS55394B1 (pt)
RU (2) RU2750540C2 (pt)
SI (2) SI2929880T1 (pt)
SM (1) SMT201700080B (pt)
TW (1) TWI603965B (pt)
WO (1) WO2015008827A1 (pt)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018137708A1 (zh) * 2017-01-26 2018-08-02 重庆莱美药业股份有限公司 一种纳米炭-铁复合体系及其组合物、制备方法和用途

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0753725B2 (ja) 1987-10-08 1995-06-07 富山化学工業株式会社 4h―1―ベンゾピラン―4―オン誘導体およびその塩、それらの製造法並びにそれらを含有する抗炎症剤
DE69427907T2 (de) * 1993-04-09 2002-04-04 Toyama Chemical Co Ltd Immunomodulator, zelladhäsionsinhibitor und mittel zur behandlung und vorbeugung von autoimmunerkrankungen
EP0868598B1 (de) * 1995-12-21 1999-10-27 Siemens Aktiengesellschaft Luftansaugvorrichtung mit variabler saugrohrlänge für eine brennkraftmaschine
DE10044091A1 (de) * 2000-09-07 2002-04-04 Merck Patent Gmbh Chromanonderivate
GB0507696D0 (en) * 2005-04-15 2005-05-25 Novartis Ag Organic compounds
GB0507695D0 (en) 2005-04-15 2005-05-25 Novartis Ag Organic compounds
WO2007042035A2 (en) * 2005-10-07 2007-04-19 Aditech Pharma Ab Combination therapy with fumaric acid esters for the treatment of autoimmune and/or inflammatory disorders
TWI606826B (zh) 2011-08-30 2017-12-01 富山化學工業股份有限公司 艾拉莫德或其鹽之用途

Also Published As

Publication number Publication date
RS55394B1 (sr) 2017-04-28
IL243550B (en) 2019-06-30
TWI603965B (zh) 2017-11-01
PL2929880T3 (pl) 2017-03-31
RU2750540C2 (ru) 2021-06-29
JP5802868B2 (ja) 2015-11-04
CN105407887A (zh) 2016-03-16
NO3078372T3 (pt) 2018-02-10
JPWO2015008827A1 (ja) 2017-03-02
ES2593527T3 (es) 2016-12-09
EP3078372A1 (en) 2016-10-12
SI2929880T1 (sl) 2016-12-30
HK1222556A1 (zh) 2017-07-07
US20160228404A1 (en) 2016-08-11
RU2016105141A (ru) 2017-08-23
CY1118140T1 (el) 2017-06-28
US9918963B2 (en) 2018-03-20
CA2918325A1 (en) 2015-01-22
SI3078372T1 (en) 2018-01-31
IL243550A0 (en) 2016-02-29
HUE029800T2 (en) 2017-04-28
SMT201700080B (it) 2017-03-08
CN105407887B (zh) 2018-09-04
CA2918325C (en) 2018-06-26
DK2929880T3 (da) 2017-01-02
AU2014291149A1 (en) 2016-02-11
PL3078372T3 (pl) 2018-02-28
CY1119496T1 (el) 2018-03-07
EP2929880B1 (en) 2016-09-14
ES2642440T3 (es) 2017-11-16
LT2929880T (lt) 2016-11-25
EP2929880A1 (en) 2015-10-14
JP2016034953A (ja) 2016-03-17
RU2641301C2 (ru) 2018-01-17
EP2929880A4 (en) 2015-10-14
JP6060231B2 (ja) 2017-01-11
HRP20171497T1 (hr) 2017-11-17
WO2015008827A1 (ja) 2015-01-22
LT3078372T (lt) 2017-11-27
RU2017131951A3 (pt) 2020-12-18
US20160228406A1 (en) 2016-08-11
TW201536764A (zh) 2015-10-01
HRP20161317T1 (hr) 2016-12-16
AU2014291149B2 (en) 2017-05-04
RU2017131951A (ru) 2019-02-06
RS56489B1 (sr) 2018-01-31
PT3078372T (pt) 2017-10-18
HUE034661T2 (en) 2018-02-28
EP3078372B1 (en) 2017-09-13
US20150353519A1 (en) 2015-12-10
DK3078372T3 (en) 2017-10-16

Similar Documents

Publication Publication Date Title
IL287516A (en) Medicinal uses of empagliflozin
HRP20190101T1 (hr) Terapeutske uporabe empagliflozina
IL268340A (en) Glucosylceramide synthase inhibitors for the treatment of diseases
IL243976A0 (en) kdm1a inhibitors for disease treatment
HK1213818A1 (zh) 依帕列淨的治療用途
EP3019491A4 (en) KINASE INHIBITORS FOR THE TREATMENT OF DISEASE
SI2981271T1 (sl) Terapevtske uporabe empagliflozina
BR302013006430S1 (pt) Configuração aplicada em cama para paciente
HK1214526A1 (zh) 眼底疾病治療劑
HUE056624T2 (hu) Szénhidrátok gyógyászati készítményei terápiás alkalmazásra
GB201313356D0 (en) Therapeutic Intervention
HK1222556A1 (zh) 基於巨噬細胞游走抑制因子的抑制作用的疾病的治療劑
EP3046629A4 (en) Treatment of inflammatory skin disease
GB201321628D0 (en) Treatment of disease
GB201320349D0 (en) New therapeutic use